The treatment of lupus nephritis with cyclophosphamide and steroids changed the prognosis of
lupus nephritis in the early '80s. In recent years, alternative regimens have appeared in
both the induction and maintenance with similar results at least to those offered by the
classic pattern and possibly with fewer side effects, especially for long term. The
association of prednison and mycophenolate has created large expectations to that effect, and
is part of first-line therapeutic arsenal of lupus nephritis type III, IV and V.
Despite the significant advances that have led to these treatments, the likelihood of
complete remission after six months remains, according to the series of 8-13% and partial
remission do not exceed 60% in papers published. In the last year, two articles have been
published supporting the use of triple therapy (prednisone, mycophenolate, cyclosporine) in
poor prognosis of lupus nephritis with hopefully better results than those obtained
previously. In this study we try to compare the effectiveness of triple therapy, the therapy
is now considered standard (prednisone, mycophenolate) in patients with lupus nephritis type
III-IV-V
Phase:
Phase 3
Details
Lead Sponsor:
Hospital Universitario Fundación Alcorcón
Collaborators:
Hospital General Universitario Gregorio Marañon Hospital Infanta Sofia Hospital Juan Canalejo Hospital Regional Universitario Carlos Haya Hospital San Pedro Alcantara. Caceres. Spain Hospital San Pedro de Alcantara Hospital Universitario 12 de Octubre Hospital Universitario de Guadalajara. Spain Hospital Universitario Infanta Leonor Hospital Universitario Ramon y Cajal Hospital Universitario Reina Sofia Hospital Universitario Reina Sofia de Cordoba Hospital Universitario Virgen de la Victoria University Hospital of the Nuestra Señora de Candelaria